Candel Therapeutics CFO Jason Amello resigns; Charles Schoch named interim CFO

Candel Therapeutics, Inc.

Jason A. Amello resigned as CFO effective Jan 12, 2024, to pursue another opportunity.
Board appointed Charles Schoch as interim CFO, effective Jan 12, 2024.
Schoch had served as VP of Finance and Corporate Controller since March 2023.
Schoch's annual base salary increased to $325,000 as interim CFO.
Schoch is a CPA with prior experience at Corbus Pharmaceuticals and PwC.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason A. Amello

Chief Financial Officer

CADL · Candel Therapeutics, Inc.

Effective: 2024-01-12
Successor: Charles Schoch
Filed: January 12, 2024, 6:59 PM ET

Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.

Appointed (interim)

Charles Schoch

interim Chief Financial Officer

CADL · Candel Therapeutics, Inc.

Effective: 2024-01-12
Filed: January 12, 2024, 6:59 PM ET

unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Jason A. Amello resigned from his position as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Charles Schoch was appointed as interim Chief Financial Officer at Candel Therapeutics, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

unanimously appointed Charles Schoch as the Company’s interim Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024.

View on SEC.gov

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-004262

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.